FogPharma

The AI engine Fit Assessment

Beta

FogPharma creates cell-penetrating mini proteins to target and neutralize cancer-causing proteins, offering new precision medicines for cancer treatment beyond conventional methods.

Blurb

FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.

HQ Location

United States

Founded

2016

Employees

51 - 200

Total funding raised

$530.27M

Last Funding Event

Series E, $145.00M, March 1, 2024

Smart insights

  • Greg Verdine (Co-Founder, President and CEO) has 12 years of experience in the Healthcare industry at companies such as Third Rock Ventures and Apple Tree Partners
  • Greg Verdine (Co-Founder, President and CEO) has 4 years of experience in the Life Sciences industry at Apple Tree Partners
  • Greg Verdine (Co-Founder, President and CEO) has 12 years of experience in the Biotechnology industry at companies such as Third Rock Ventures and Apple Tree Partners
  • Sandra Smith (Vice President, People) worked at Microsoft as New England Research & Development Site HR Leader for 8.5 years (2011 - 2019)
  • Alana Golden (Founder, Chair) worked at Microsoft in various roles, including Learning And Development Specialist, for a total of 2.5 years (2018 - 2021)
  • Greg Verdine (Co-Founder, President and CEO) holds a PhD, Chemistry from Columbia University in the City of New York (1981 - 1986)
  • John McGee (Scientific Founder, Head of De Novo Discovery) holds a BS, Chemistry from Stanford University (2004 - 2008)
  • John McGee (Scientific Founder, Head of De Novo Discovery) holds a PhD, Biochemistry from Harvard University (2008 - 2013)
  • 6m headcount growth: 4%
  • 1Y headcount growth: 9%
  • Headcount-to-last-round ratio: 13.6 employees/$M

Developer of cell-penetrating mini proteins (CPMPs) designed to target cancer-causing proteins inside cancer cells and neutralize them. The company's mini proteins (CPMPs) are a broad new class of medicines that can drug target beyond the reach of conventional therapeutics, enabling physicians to treat cancer-related diseases.